Navigation Links
Onyx Pharmaceuticals Reports 2008 First Quarter Results
Date:5/6/2008

of March 31, 2008, the company had cash, cash equivalents, and short and long-term marketable securities of $456.6 million compared to $469.7 million at December 31, 2007. This decrease was primarily due to cash used in operations for the three months ended March 31, 2008.

Conference Call with Management Today

Onyx's management will host a teleconference and webcast to provide an update on Nexavar and discuss first quarter 2008 financial results. The event will begin at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on May 6, 2008. Interested parties may access a live webcast of the presentation on our website at:

http://www.onyx-pharm.com/wt/page/event_calendar

or by dialing 630-691-2760 and using the passcode 21488196. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 21488196 approximately one hour after the teleconference concludes. The replay will be available through June 6, 2008.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer by changing the way cancer is treated(TM). The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar(R) (sorafenib) tablets, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer and other cancers. For more information about Onyx, visit the company's website at: http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals Inc.

This news release contains "forward-looking statements" of Onyx within
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Calif. , April 17, 2015 /PRNewswire/ ... received a SBIR grant from the National ... National Institutes of Health (NIH). The grant ... efforts in the development of breakthrough genomic ... using specially fabricated substrates. Centrillion has been ...
(Date:4/17/2015)... , April 17, 2015  Guggenheim Securities, the ... today announced the hiring of William Tanner ... Mr. Tanner will start work at Guggenheim ... York office. "Bill brings a ... research, to our experienced and highly acclaimed healthcare team," ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 BellBrook ... and marketing support for the powerful Orthogonal Pooled ... Chemical Genomics Center at the Lankenau Institute for ... mission is to measurably improve successful drug discovery ... by offering rare, drug-like libraries available nowhere else, ...
(Date:4/16/2015)... Francisco, CA (PRWEB) April 16, 2015 ... scheduled to report first quarter results on Thursday, April ... announcement, Cytokinetics’ senior management will host a conference call ... financial results and the company’s outlook for the future. ... can be accessed from the homepage and in the ...
Breaking Biology Technology:Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3
... , , , , ... FastStart Taq DNA Polymerase , , ... chemically modified version,of Taq DNA Polymerase for hot start PCR, was introduced,in 2000. Based on the ... preparation,currently available , , , , ...
... , , , , , , ... Synthesis with the new Transcriptor Reverse, Transcriptase , ... With the new recombinant ,Transcriptor Reverse Transcriptase, you will , , , ... cDNA transcripts , Reverse transcribe difficult templates with high secondary structure , ...
... , , , , , ... , , Co-transfections , ... constructs work in your cell line. Also, determine the ratio of DNA ,to FuGENE 6 ... good expression levels. Then, perform the transfection, ensuring the ,DNA / FuGENE 6 Reagent ratio ...
Cached Biology Technology:Challenge the Performance of Your Hot-Start PCRs,with FastStart Taq DNA Polymerase and,the Novel FastStart High Fidelity PCR System 2Transcriptor Reverse Transcriptase 2Transcriptor Reverse Transcriptase 3Transcriptor Reverse Transcriptase 4Transcriptor Reverse Transcriptase 5Uses and Applications of FuGENE 6 Transfection Reagent 2
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/10/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) ... Profiles - NEC" report to their offering. ... continue to supply a range of IT security management ... focus on the development of a Big Data and ... the Asia-Pacific region is a ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... western corn rootworm beetle, a pest that feasts on corn ... billion annually in the U.S., also can survive on the ... crop that would likely be grown alongside corn, researchers report. ... Miscanthus rhizomes, and adult beetles will lay their eggs ...
... St. Louis, MO, January 5, 2010 With obesity rising ... important weight management strategy. Since people who are trying to ... "lower in calories" or "reduced-energy" in restaurants and supermarkets, it ... study published in the January 2010 issue of the ...
... what amounted to a kind of census of sweet corn ... in Illinois, Wisconsin, and Minnesota shed light on what works ... the results also revealed some of the more complicated relationships ... in the Midwest. "Rather than a typical controlled field ...
Cached Biology News:Miscanthus, a biofuels crop, can host western corn rootworm 2Miscanthus, a biofuels crop, can host western corn rootworm 3Restaurant and packaged foods can have more calories than nutrition labeling indicates 2Sweet corn study provides large-scale picture of better fields 2Sweet corn study provides large-scale picture of better fields 3